| Item Type | Name |
|
Concept
|
Mutation
|
|
Concept
|
Germ-Line Mutation
|
|
Concept
|
Point Mutation
|
|
Concept
|
Mutation, Missense
|
|
Academic Article
|
The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin.
|
|
Academic Article
|
Molecular abnormalities in lung cancer.
|
|
Academic Article
|
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
|
|
Academic Article
|
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
|
|
Academic Article
|
Targeting c-Kit mutations: basic science to novel therapies.
|
|
Academic Article
|
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
|
|
Academic Article
|
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
|
|
Academic Article
|
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
|
|
Academic Article
|
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
|
|
Academic Article
|
c-Met: structure, functions and potential for therapeutic inhibition.
|
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
|
Academic Article
|
Expression and mutational analysis of MET in human solid cancers.
|
|
Academic Article
|
Role of c-Met in cancer: emphasis on lung cancer.
|
|
Academic Article
|
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
|
|
Academic Article
|
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
|
|
Academic Article
|
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.
|
|
Academic Article
|
MET receptor tyrosine kinase.
|
|
Academic Article
|
Ethnic differences and functional analysis of MET mutations in lung cancer.
|
|
Academic Article
|
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
|
|
Academic Article
|
Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.
|
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
|
Academic Article
|
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.
|
|
Academic Article
|
Tyrosine kinase mutations in human cancer.
|
|
Academic Article
|
c-Met is a potentially new therapeutic target for treatment of human melanoma.
|
|
Academic Article
|
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.
|
|
Academic Article
|
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
|
|
Academic Article
|
Personalized treatment of lung cancer.
|
|
Academic Article
|
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.
|
|
Academic Article
|
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
|
|
Academic Article
|
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
|
|
Academic Article
|
Involvement of the adapter protein CRKL in integrin-mediated adhesion.
|
|
Academic Article
|
C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.
|
|
Academic Article
|
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
|
|
Academic Article
|
Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease.
|
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
|
Academic Article
|
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
|
|
Academic Article
|
MET as a possible target for non-small-cell lung cancer.
|
|
Academic Article
|
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
|
|
Academic Article
|
Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer.
|
|
Academic Article
|
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.
|
|
Academic Article
|
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
|
|
Academic Article
|
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
|
|
Academic Article
|
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
|
|
Academic Article
|
Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy.
|
|
Academic Article
|
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
|
|
Academic Article
|
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
|
|
Academic Article
|
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
|
|
Academic Article
|
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.
|
|
Academic Article
|
Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
|
|
Academic Article
|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
|
|
Academic Article
|
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer.
|
|
Academic Article
|
Genomic mutation-driven metastatic breast cancer therapy: a single center experience.
|
|
Academic Article
|
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
|
|
Academic Article
|
Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.
|
|
Academic Article
|
Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2.
|
|
Academic Article
|
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
|
|
Academic Article
|
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
|
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
|
Academic Article
|
Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience.
|
|
Academic Article
|
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
|
|
Academic Article
|
Untying the gordion knot of targeting MET in cancer.
|
|
Academic Article
|
The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer.
|
|
Academic Article
|
Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
|
|
Academic Article
|
Targeted Therapies in Non-small-Cell Lung Cancer.
|
|
Academic Article
|
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.
|
|
Academic Article
|
Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases.
|
|
Academic Article
|
The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy.
|
|
Academic Article
|
Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.
|
|
Academic Article
|
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report.
|
|
Academic Article
|
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
|
|
Academic Article
|
Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
|
|
Academic Article
|
Germline mutations and age at onset of lung adenocarcinoma.
|
|
Academic Article
|
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
|
|
Academic Article
|
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.
|
|
Academic Article
|
The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients.
|
|
Academic Article
|
Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.
|
|
Academic Article
|
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor.
|
|
Academic Article
|
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk.
|
|
Grant
|
Role of Paxillin in Lung Cancer
|
|
Grant
|
Role of c-Met in SCLC and Potential for Novel Therapy
|
|
Grant
|
Novel Targeted Therapy in Pancreatic Cancer
|
|
Grant
|
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
|
|
Academic Article
|
Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status.
|
|
Academic Article
|
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
|
|
Academic Article
|
A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer.
|